The studies available in the literature concerning the level of CD69+ expression on the T lymphocytes have shown that the level of this marker measured in peripheral blood samples in patients with head and neck cancer was lower in patients with cancer as compared to a control group, but these differences have not been shown to be statistically significant [30,31]. This evidence concerns the gene CD69 and cancer.